drugset
Drugs / Henagliflozin
last change Jul 2026 re-read 2 minutes ago

Henagliflozin

also known as SHR3824

Small molecule targets SLC5A2 via inhibition

Developed for
type 2 diabetes mellitus · heart failure · obesity disorder · prediabetes syndrome · chronic kidney disease · cognitive impairment with or without cerebellar ataxia · diabetic kidney disease · hypertrophic cardiomyopathy
+5 more · metabolic dysfunction-associated steatotic liver disease · myocardial infarction · NAFLD1 · atrial fibrillation · kidney failure
Investigated by
Jiangsu HengRui Medicine Co., Ltd. · Shandong Suncadia Medicine Co., Ltd. · Second Affiliated Hospital of Soochow University · Affiliated Hospital of Jiangsu University · Bin Lu · Fifth Affiliated Hospital, Sun Yat-Sen University
+25 more · First Affiliated Hospital of Guangxi Medical University · First Affiliated Hospital of Wannan Medical College · Jiangsu Hengrui Pharmaceutical Co., Ltd. · Northern Jiangsu People's Hospital · Qian geng · Qianfoshan Hospital · RenJi Hospital · Second Affiliated Hospital, School of Medicine, Zhejiang University · Shandong Provincial Hospital · Shanghai East Hospital · Shanxi Provincial People's Hospital · Sir Run Run Shaw Hospital · The Affiliated Hospital of Xuzhou Medical University · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · The First Affiliated Hospital of Air Force Medicial University · The First Affiliated Hospital of Soochow University · The First People's Hospital of Changzhou · The First People's Hospital of Lianyungang · The Second Affiliated Hospital of Shandong First Medical University · The Second Hospital of Nanjing Medical University · The fourth affiliated hospital of nantong university · Wuxi People's Hospital · Xiqiao Zhou · Zhejiang Provincial People's Hospital · Zhongnan Hospital

Trials 31 · a red edge is where a trial was stopped

today NCT07687212 · Ph 1/2 NCT07294495 · not/applicable NCT07323381 · Ph 4 NCT07027774 · Ph 4 NCT06888050 · Ph 4 NCT06762223 · Ph 4 NCT06448130 · Ph 4 NCT06085703 · not/applicable NCT06216340 · Ph 4 NCT06218342 · Ph 4 NCT06031389 · not/applicable NCT06059287 · not/applicable NCT06187727 · Ph 4 NCT05742230 · not/applicable NCT05677334 · Ph 4 NCT05692934 · Ph 1 NCT05682495 · Ph 1 NCT05120219 · Ph 1 NCT06083116 · Ph 1 NCT03329118 · Ph 1 NCT04390295 · Ph 3 NCT03159052 · Ph 3 NCT03160014 · Ph 1 NCT02500485 · Ph 1 NCT02366377 · Ph 1 NCT02366351 · Ph 1 NCT02354027 · Ph 1 NCT02346175 · Ph 1 NCT02353975 · Ph 1 NCT02361138 · Ph 1 NCT02356224 · Ph 1
20132014201520162017201820192020202120222023202420252026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 114 trials
Phase 1 NCT05692934 Jan → Mar 2023 type 2 diabetes mellitus Shandong Suncadia Medicine Co., Ltd. Completed No outcome recorded
Phase 1 NCT05682495 Jan → Apr 2023 type 2 diabetes mellitus Shandong Suncadia Medicine Co., Ltd. Completed No outcome recorded
Phase 1 NCT05120219 Oct → Nov 2021 type 2 diabetes mellitus Shandong Suncadia Medicine Co., Ltd. Unknown No outcome recorded
Phase 1 NCT06083116 Aug → Oct 2019 type 2 diabetes mellitus Jiangsu HengRui Medicine Co., Ltd. Completed No outcome recorded
Phase 1 NCT03329118 Nov → Dec 2017 type 2 diabetes mellitus Jiangsu HengRui Medicine Co., Ltd. Unknown No outcome recorded
Phase 1 NCT03160014 Jun 2015 → Dec 2017 — Jiangsu HengRui Medicine Co., Ltd. Unknown No outcome recorded
Phase 1 NCT02500485 May → Jul 2015 type 2 diabetes mellitus Jiangsu HengRui Medicine Co., Ltd. Unknown No outcome recorded
Phase 1 NCT02366377 Feb 2015 → Mar 2016 type 2 diabetes mellitus Jiangsu HengRui Medicine Co., Ltd. Unknown No outcome recorded
Phase 1 NCT02366351 Feb 2015 → Jan 2016 type 2 diabetes mellitus Jiangsu HengRui Medicine Co., Ltd. Unknown No outcome recorded
Phase 1 NCT02354027 Sep → Nov 2014 type 2 diabetes mellitus Jiangsu HengRui Medicine Co., Ltd. Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT07687212 Jul 2026 → Sep 2027 expected heart failure The First Affiliated Hospital of Air Force Medicial University Not yet recruiting No outcome recorded
Phase 32 trials
Phase 3 NCT04390295 Nov 2017 → May 2020 type 2 diabetes mellitus Jiangsu HengRui Medicine Co., Ltd. Unknown No outcome recorded
Phase 3 NCT03159052 Jun 2017 → Oct 2018 type 2 diabetes mellitus Jiangsu HengRui Medicine Co., Ltd. Unknown No outcome recorded
Phase 49 trials
Phase 4 NCT07323381 Dec 2025 → Sep 2027 expected type 2 diabetes mellitus Bin Lu Not yet recruiting No outcome recorded
Phase 4 NCT07027774 Jul 2025 → Dec 2027 expected chronic kidney disease First Affiliated Hospital of Wannan Medical College Not yet recruiting No outcome recorded
Phase 4 NCT06888050 Apr 2025 → Jun 2026 overdue type 2 diabetes mellitus Zhejiang Provincial People's Hospital Recruiting No outcome recorded
Phase 4 NCT06762223 Dec 2024 → Dec 2026 expected metabolic dysfunction-associated steatotic liver disease, type 2 diabetes mellitus Xiqiao Zhou Not yet recruiting No outcome recorded
Phase 4 NCT06448130 Jun 2024 → Dec 2026 expected prediabetes syndrome, type 2 diabetes mellitus Shandong Provincial Hospital Not yet recruiting No outcome recorded
Phase 4 NCT06216340 Feb 2024 → Oct 2026 expected obesity disorder, prediabetes syndrome The First People's Hospital of Changzhou Not yet recruiting No outcome recorded
Phase 4 NCT06218342 Feb 2024 → Dec 2025 NAFLD1, type 2 diabetes mellitus Sir Run Run Shaw Hospital Unknown No outcome recorded
Phase 4 NCT06187727 Jul 2023 → Jan 2025 heart failure, myocardial infarction Qian geng Completed No outcome recorded
Phase 4 NCT05677334 Mar 2023 → Oct 2024 type 2 diabetes mellitus First Affiliated Hospital of Guangxi Medical University Completed No outcome recorded
Phase not applicable5 trials
— NCT07294495 Jan 2026 → Dec 2028 expected hypertrophic cardiomyopathy Shanghai East Hospital Not yet recruiting No outcome recorded
— NCT06085703 Apr 2024 → Jun 2025 cognitive impairment with or without cerebellar ataxia, type 2 diabetes mellitus The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Completed No outcome recorded
— NCT06031389 Jan → Dec 2024 diabetic kidney disease Qianfoshan Hospital Unknown No outcome recorded
— NCT06059287 Oct 2023 → Dec 2025 obesity disorder, type 2 diabetes mellitus RenJi Hospital Unknown No outcome recorded
— NCT05742230 Apr 2023 → Jul 2024 heart failure Second Affiliated Hospital, School of Medicine, Zhejiang University Unknown No outcome recorded
Also used as a comparator or background therapy in 2 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT03159832 Comparator Jun 2015 → Dec 2017 kidney failure Jiangsu HengRui Medicine Co., Ltd. Unknown No outcome recorded
Phase 31 trial
Phase 3 NCT05252624 Comparator Sep 2022 → Sep 2023 atrial fibrillation Beijing Anzhen Hospital Unknown No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 34 sources stand behind the page.

FieldValueCited text
Known as Henagliflozin “Primary anti-HF therapy + Henagliflozin Proline Tablets (10mg, 1 times/day) + clostridial enterococcus triple live tablet (400mg, 3 times/day) orally, for 12 weeks.” NCT07687212 ↗
16

NCT07294495 ↗

NCT07323381 ↗

NCT06031389 ↗

NCT06187727 ↗

NCT06083116 ↗

NCT05252624 ↗

NCT06216340 ↗

NCT05677334 ↗

NCT06448130 ↗

NCT06085703 ↗

NCT06762223 ↗

NCT06059287 ↗

NCT05742230 ↗

NCT07027774 ↗

NCT06888050 ↗

NCT06218342 ↗
Known as SHR3824 “Henagliflozin (SHR3824) is a hypoglycemic agent classified as an SGLT2i, which has been independently developed by Jiangsu Hengrui Pharmaceutical Co., Ltd. (China) and Shanghai...” NCT06762223 ↗
16

“The purpose of this study is to assess the effect of food on the single-dose PK of SHR3824, SP2086 and metformin in the HR20031 FDC tablets in healthy subjects.” NCT05692934 ↗

“Subjects will receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2 followed by 7 days washout” NCT05682495 ↗

“single-dose PK of SHR3824 and metformin administered in the HR20033 FDC tablet” NCT05120219 ↗

NCT02353975 ↗

NCT02500485 ↗

NCT04390295 ↗

NCT02361138 ↗

NCT03159052 ↗

NCT02346175 ↗

NCT03160014 ↗

NCT02356224 ↗

NCT02354027 ↗

NCT03159832 ↗

NCT03329118 ↗

NCT02366377 ↗

NCT02366351 ↗
Action Inhibit “SHR3824(a Sodium-Glucose Cotransporter 2 inhibitor)” NCT02354027 ↗
1

“Sodium/glucose cotransporter 2 inhibitor” CHEMBL4297431 ↗
Modality Small molecule — CHEMBL4297431 ↗
Route Oral “single and multiple oral doses of 5mg to 20 mg SHR3824 in Type 2 diabetes mellitus patients.” NCT02346175 ↗
Target SLC5A2 “Sodium/glucose cotransporter 2 inhibitor” CHEMBL4297431 ↗